OpenURL Connection Search

Select item for more details and to access through your institution.

Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.
Published in:
European Journal of Neurology, 2016, v. 23, n. 4, p. 796, doi. 10.1111/ene.12942
By:
- Constantinescu, R.;
- Krýsl, D.;
- Bergquist, F.;
- Andrén, K.;
- Malmeström, C.;
- Asztély, F.;
- Axelsson, M.;
- Menachem, E. B.;
- Blennow, K.;
- Rosengren, L.;
- Zetterberg, H.
Publication type:
Article
Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.
Published in:
2013
By:
- Tedeholm, H;
- Lycke, J;
- Skoog, B;
- Lisovskaja, V;
- Hillert, J;
- Dahle, C;
- Fagius, J;
- Fredrikson, S;
- Landtblom, A-M;
- Malmeström, C;
- Martin, C;
- Piehl, F;
- Runmarker, B;
- Stawiarz, L;
- Vrethem, M;
- Nerman, O;
- Andersen, O
Publication type:
Case Study
Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
Published in:
Journal of Neurology, 2011, v. 258, n. 5, p. 882, doi. 10.1007/s00415-010-5863-2
By:
- Axelsson, M.;
- Malmeström, C.;
- Nilsson, S.;
- Haghighi, S.;
- Rosengren, L.;
- Lycke, J.
Publication type:
Article
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
Published in:
Acta Neurologica Scandinavica, 2013, v. 128, n. 6, p. e33, doi. 10.1111/ane.12151
By:
- Kuhle, J.;
- Malmeström, C.;
- Axelsson, M.;
- Plattner, K.;
- Yaldizli, Ö.;
- Derfuss, T.;
- Giovannoni, G.;
- Kappos, L.;
- Lycke, J.
Publication type:
Article
Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis.
Published in:
Multiple Sclerosis (13524585), 2009, v. 15, n. 4, p. 448, doi. 10.1177/1352458508100031
By:
- Mattsson, N.;
- Axelsson, M.;
- Haghighi, S.;
- Malmeström, C.;
- Wu, G.;
- Anckarsäter, R.;
- Sankaranarayanan, S.;
- Andreasson, U.;
- Fredrikson, S.;
- Gundersen, A.;
- Johnsen, L.;
- Fladby, T.;
- Tarkowski, A.;
- Trysberg, E.;
- Wallin, A.;
- Anckarsäter, H.;
- Lycke, J.;
- Andersen, O.;
- Simon, A. J.;
- Blennow, K.
Publication type:
Article
Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study.
Published in:
Multiple Sclerosis Journal, 2024, v. 30, n. 6, p. 664, doi. 10.1177/13524585241237388
By:
- Johnsson, M;
- Stenberg, YT;
- Farman, HH;
- Blennow, K;
- Zetterberg, H;
- Malmeström, C;
- Sandgren, S;
- Rosenstein, I;
- Lycke, J;
- Axelsson, M;
- Novakova, L
Publication type:
Article

Found: 6

Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.

Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis.

Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study.